• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2023 Fiscal Year Final Research Report

Radioceranostics Drug Design Strategy for Tumor-Targeting Nanoparticles for Clinical Use

Research Project

  • PDF
Project/Area Number 21K07653
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 52040:Radiological sciences-related
Research InstitutionTohoku Medical and Pharmaceutical University

Principal Investigator

YAMAMOTO Fumihiko  東北医科薬科大学, 薬学部, 教授 (40253471)

Project Period (FY) 2021-04-01 – 2024-03-31
Keywordsラジオセラノスティクス / 分子イメージング / 放射性標識合成 / 腫瘍 / ナノ粒子
Outline of Final Research Achievements

I investigated the validity of a new drug design for the realization of "lactosomes," which evade the Accelarated Blood Clearance (ABC) phenomenon while keeping not only specific tumor accumulation but also stealth properties, with the aim of creating radio-theranostics. Ideveloped a new 111In-labeled lactosome, which can be substituted for 90Y, using AB-type lactosomes as the nucleus, and evaluated its biodistribution in tumor model mice and tumor accumulation, and obtained new findings. In addition, a newly designed lactosome with a polyglycerol functional group, which is expected to evade the ABC phenomenon, was developed, and the amount of antibody produced in blood after administration was reduced compared to that of lactosomes.

Free Research Field

放射薬学、放射性薬品科学、分子イメージング薬学

Academic Significance and Societal Importance of the Research Achievements

PEGリポソームなど化学療法のDDS基材としてナノキャリアが多く開発され、EPR効果を利用した腫瘍治療薬剤として上市されたものもあるが、分子イメージング基材やセラノスティクス基剤として確立するには解決すべき課題がある。
本研究によりラクトソーム構成ポリマーに機能付加を行うことで、血中抗体量を低減させることが可能になった。評価にはインビボでのABC現象回避や腫瘍集積性の検討がさらに必要だが、今後ナノ粒子機能付の妥当性が明らかとなれば、がん診断だけでなく治療精度の向上にも寄与できるセラノスティクス製剤としてのナノ粒子開発に道を拓くものと期待される。

URL: 

Published: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi